Sandoz Reveals European Natalizumab Launch Amid GLP-1 Ambitions
European Commission Approval Last Year Promised H1 2024 Roll-Out For MS Treatment
Sandoz arrived in California for its first J.P. Morgan Annual Healthcare Conference as an independent company. As well as revealing its first natalizumab biosimilar launch, the firm spoke at length about how it will look to capitalize on the growing GLP-1 market in the years ahead.
